This article, published in the esteemed journal Blood Science, highlights the intricate role of gut microbiota in hematopoiesis, encompassing its influence on both benign and malignant conditions. As a peer-reviewed platform at the forefront of clinical and experimental hematology, Blood Science is recognized for its impact on advancing our understanding of molecular biology, physiology, and clinical applications. Authored by Professor Tao Cheng from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Med-ical College, Professor Hui Cheng from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Med-ical College and Professor Pengxu Qian from the First Affiliated Hospital, Zhejiang University School of Medicine，this work provides crucial insights into the therapeutic implications of gut microbiota for hematological health and disease management.

Blood Science, an authoritative journal in the fields of hematology and oncology, has been at the forefront of advancing knowledge in blood-related disorders. Dedicated to publishing pioneering research, the journal provides a platform for understanding the complexities of blood ecosystems, from cellular mechanisms to clinical implications. By fostering collaboration and disseminating groundbreaking studies, Blood Science has shaped the way researchers and clinicians approach hematological health and disease.

This article, published in the journal Blood Science, elucidates groundbreaking advancements in understanding the endothelial origins of the hematopoietic system. As a leading platform in clinical and experimental hematology, Blood Science continues to publish high-impact research that transforms molecular biology and physiology. Authored by Professor Yu Lan from the Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University and Professor Bing Liu from the Fifth Medical Center, Chinese PLA General Hospital, this study delves into the complex cellular evolution of hemogenic endothelial cells (HECs), the molecular mechanisms driving endothelial-to-hematopoietic transition (EHT), and the striking parallels between human and mouse systems. These insights mark a significant leap toward regenerative medicine and innovative treatments for hematological disorders.

New findings from the ECOG-ACRIN EA4151 Phase 3 trial, published in Blood on November 25, 2024, could change clinical practice for mantle cell lymphoma (MCL).For years, autologous hematopoietic cell transplantation…